![1C6 [LS77-1C6]](http://www.family998.com/static/images/cells-no_picture.jpg)
-
平臺(tái)編號(hào)：bio-69035
-
國(guó)際編號(hào)：HB-12330?
-
細(xì)胞信息： 1C6 [LS77-1C6]
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
1C6 [LS77-1C6]
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
ATCC Number：HB-12330?
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
數(shù)量：大量
免疫類(lèi)型：IgG1 kappa
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：0.5mg Designations: 1C6 [LS77-1C6]
Depositors: ?LeukoSite, Inc.
Isotype: IgG1 kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology:
Source: Cell Type: hybridoma: lymphoblast B lymphocyte; somatic cell hybrid
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a synthetic peptide corresponding to the first 37 N-terminal amino acids of CXCR3. Spleen cells were fused with Sp2/0 myeloma cells. The antibody recognizes surface expressed CXCR3, as judged by staining of CXCR3 transfected cells, but not untransfected cells. The antibody also stained human T cells and T cell clones that had been activated in vitro with PHA or anti-CD3. However, the anti-CXCR3 antibody did not react with neutrophils. The CXCR3 receptor is also known as the IP-10 receptor and the Mig receptor.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml.Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Do not allow the cell density to exceed 1 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 71339: Loetscher M, et al. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor. US Patent 6,184,358 dated Feb 6 2001
88724: Qin S, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754, 1998. PubMed: 9466968
88725: Loetscher P, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276: 2986-2991, 2001. PubMed: 11110785
88726: Till S, et al. T cell phenotypes of the normal nasal mucosa: induction of Th2 cytokines and CCR3 expression by IL-4. J. Immunol. 166: 2303-2310, 2001. PubMed: 11160286
88727: Jones D, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96: 685-690, 2000. PubMed: 10887135
ATCC Number：HB-12330?
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
數(shù)量：大量
免疫類(lèi)型：IgG1 kappa
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：0.5mg Designations: 1C6 [LS77-1C6]
Depositors: ?LeukoSite, Inc.
Isotype: IgG1 kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology:
Source: Cell Type: hybridoma: lymphoblast B lymphocyte; somatic cell hybrid
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a synthetic peptide corresponding to the first 37 N-terminal amino acids of CXCR3. Spleen cells were fused with Sp2/0 myeloma cells. The antibody recognizes surface expressed CXCR3, as judged by staining of CXCR3 transfected cells, but not untransfected cells. The antibody also stained human T cells and T cell clones that had been activated in vitro with PHA or anti-CD3. However, the anti-CXCR3 antibody did not react with neutrophils. The CXCR3 receptor is also known as the IP-10 receptor and the Mig receptor.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml.Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Do not allow the cell density to exceed 1 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 71339: Loetscher M, et al. IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor. US Patent 6,184,358 dated Feb 6 2001
88724: Qin S, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101: 746-754, 1998. PubMed: 9466968
88725: Loetscher P, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276: 2986-2991, 2001. PubMed: 11110785
88726: Till S, et al. T cell phenotypes of the normal nasal mucosa: induction of Th2 cytokines and CCR3 expression by IL-4. J. Immunol. 166: 2303-2310, 2001. PubMed: 11160286
88727: Jones D, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96: 685-690, 2000. PubMed: 10887135
